MultiCell Chooses CRO To Manage MCT-125 Phase IIb Clinical Trial

The trial, which is to be conducted in the UK, will evaluate the company’s lead drug candidate, MCT-125 for treatment of primary multiple sclerosis-related fatigue (PMSF).

MultiCell said that in Phase IIa study MCT-125 was effective within 4 weeks of administration and was active across all multiple sclerosis (MS) disease severity assessment scales, and on patients regardless of MS disease sub-type.

MCT-125 is a fixed dose, orally delivered, combination therapeutic acting on noradrenergic neurons and tyrosine hydroxylase to block the reuptake of noradrenaline with little or no direct action on serotoninergic neurons.

The synthesis of noradrenaline in noradrenergic neurons is tightly regulated by tyrosine hydroxylase acting as the key rate-limiting step. MCT-125 is thought to lead to the greater availability of noradrenaline in the central nervous system resulting in a decrease in fatigue levels.

CDSS is a clinical research organisation specialising in the management of clinical trials including the provision of study site coordination/research nursing services.